Isoform selective kinase inhibitor - Allorion Therapeutics
Latest Information Update: 17 Oct 2024
Price :
$50 *
At a glance
- Originator Allorion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 17 Oct 2024 Early research in Cancer in China (unspecified route), prior to October 2024 (Allorion Therapeutics pipeline, October 2024)
- 17 Oct 2024 Early research in Cancer in USA (unspecified route), prior to October 2024 (Allorion Therapeutics pipeline, October 2024)